Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Pfizer Inc (PFE) Price & Performance

iShares MSCI United Kingdom (FTSE)Trade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI United Kingdom (FTSE) vs Pfizer Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $48.28, while Pfizer Inc trades at $26.61 (market cap $154.18B). The key difference: Pfizer Inc pays a 6.36% dividend while iShares MSCI United Kingdom (FTSE) pays none, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.

EWUPFE
Sector
Broad Market / FactorHealth
52-Week High
$48.68$28.56
52-Week Low
$40.90$23.60
Market Cap
$154.18B
Volume
29,869,932
Enterprise Value
$205.67B
Dividend Yield
6.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI United Kingdom (FTSE)

EWU, the iShares MSCI United Kingdom ETF, trades at $48.64, up 0.7% with strong bullish technical signals from moving averages. The ETF shows mixed institutional activity with recent purchases by Balefire LLC and Fifth Third Bancorp offset by Bank of America trimming its position. UK market sentiment remains influenced by Middle East tensions, oil price volatility, and new political leadership under Prime Minister Andy Burnham.

The ETF's outlook balances UK economic resilience against geopolitical risks. Investment opportunity lies in exposure to FTSE 100 companies amid potential economic stabilization, while risks include ongoing Middle East tensions affecting energy markets and uncertainty around new UK fiscal policies under the Burnham administration.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI United Kingdom (FTSE)

EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.

Read more on EWU

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE